Certified Diabetes Educator Practice Exam

In the management of hypertension in a patient with diabetic nephropathy, including an ACE inhibitor in the treatment regimen is considered best practice. ACE inhibitors, or angiotensin-converting enzyme inhibitors, have specific renal protective effects that are particularly beneficial for individuals with diabetes and kidney disease. They function by inhibiting the renin-angiotensin-aldosterone system (RAAS), which helps lower blood pressure and reduce proteinuria—a key aspect of managing diabetic nephropathy.

Utilizing an ACE inhibitor not only aids in controlling hypertension but also directly mitigates the progression of kidney damage in diabetic patients. Studies have shown that these medications can improve renal outcomes, making them a cornerstone in the treatment strategy for this patient population.

While other drug classes, such as diuretics and beta-blockers, can be involved in hypertension management, they do not provide the same protective effect on the kidneys that ACE inhibitors do. Calcium channel blockers also serve a role in blood pressure control but lack the renal benefits associated with ACE inhibitors. Hence, prioritizing an ACE inhibitor aligns with best practices for both hypertension management and diabetic nephropathy care.